A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone - Full Text View

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000788

Purpose

To evaluate the pharmacokinetics and safety of concomitant administration of methadone and fluconazole.

Injection drug users constitute the second largest subset of the U.S. population at risk for HIV infection and AIDS-associated mortality. Narcotic addiction is often treated by use of methadone. Fluconazole has been shown to be highly effective in treating symptomatic mucosal candidiasis, but it is unknown whether fluconazole affects methadone metabolism, which could result in symptoms of methadone withdrawal or overdose in patients taking the drugs in combination.

Condition	Intervention	Phase
Candidiasis HIV Infections	Drug: Methadone hydrochloride Drug: Fluconazole	Phase I

MedlinePlus related topics: AIDS Yeast Infections

Drug Information available for: Methadone Methadone hydrochloride Clotrimazole Miconazole Miconazole nitrate Tioconazole Fluconazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Parallel Assignment, Safety Study
Official Title:	A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

24

Detailed Description:

Injection drug users constitute the second largest subset of the U.S. population at risk for HIV infection and AIDS-associated mortality. Narcotic addiction is often treated by use of methadone. Fluconazole has been shown to be highly effective in treating symptomatic mucosal candidiasis, but it is unknown whether fluconazole affects methadone metabolism, which could result in symptoms of methadone withdrawal or overdose in patients taking the drugs in combination.

Patients are randomized to receive methadone plus either fluconazole or placebo in clinic daily for 16 days. Study drugs are administered as close to 8 AM as possible. Patients must visit the Fort Greene clinic on study days 1, 2, 15, and 16; they may receive treatment at their home clinics on days 3 through 14.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Antiretroviral therapy.
Intermittent acetaminophen, aspirin, and ibuprofen.

Patients must have:

CD4 count >= 250 cells/mm3 within 3 months prior to study entry.
Received a stable dose of methadone for a minimum of 30 days prior to study entry.
Negative urine toxicology screen (except for methadone or methadone metabolites) within 14 days prior to study entry.
Reasonably good health.
Life expectancy of at least 6 months.
Ability and willingness to comply with protocol requirements.

NOTE:

Patients will be recruited from the methadone maintenance treatment program currently administered by Addiction Research and Treatment Corporation. Enrollment of women is encouraged.

NOTE:

Patients who are currently enrolled in CPCRA treatment and prophylaxis trials are eligible for this study provided they have been permanently removed from study drug on the other protocol.

Prior Medication:

Required:

Stable dose of methadone for a minimum of 30 days prior to study entry.

Allowed:

Prior antiretroviral therapy (dose should be stable for 14 days prior to study entry).

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Known sensitivity to azoles, methadone, and other opiate narcotics.

Concurrent Medication:

Excluded:

Amiodarone.
Anesthetics, general.
Barbiturates.
Carbamazepine.
Cimetidine.
Ciprofloxacin.
Dexamethasone.
Disulfiram.
Erythromycin.
Fluoroquinolones.
Fluoxetine.
Gestodene.
Hydrochlorothiazide.
Hypoglycemics, oral.
Isoniazid.
Itraconazole.
Ketoconazole.
Levomepromazine.
MAO inhibitors.
Methoxsalen.
Nafcillin.
Narcotic analgesics.
Naringenin.
Norethindrone.
Omeprazole.
Pentazocine.
Phenothiazines.
Phenytoin.
Quinidine.
Ranitidine.
Rifabutin.
Rifampin.
Sedative hypnotics.
Sulfaphenazole.
Tranquilizers.
Tricyclic antidepressants.
Troleandomycin.
Warfarin.

Prior Medication:

Excluded within 30 days prior to study entry:

Ketoconazole, fluconazole, or itraconazole.
Experimental drugs.

Alcohol or illicit drug abuse.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000788

Locations

United States, New York
Addiction Research and Treatment Corp
Brooklyn, New York, United States, 11201

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

Study Chair:	Cobb M
Study Chair:	Letts A

More Information

Click here for more information about Fluconazole This link exits the ClinicalTrials.gov site

Publications:

Cobb M, Desai J, Brown LS, Zannikos P, Trapnell C, Rainey P. The effect of fluconazole on the clinical pharmacokinetics of methadone. Int Conf AIDS. 1996 Jul 7-12;11(1):88 (abstract no MoB1196)

Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther. 1998 Jun;63(6):655-62.

Study ID Numbers:	CPCRA 030
Study First Received:	November 2, 1999
Last Updated:	August 25, 2008
ClinicalTrials.gov Identifier:	NCT00000788
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Methadone
Drug Interactions
Drug Therapy, Combination
Fluconazole

Antifungal Agents
Acquired Immunodeficiency Syndrome
AIDS-Related Complex

Study placed in the following topic categories:

Fluconazole
Sexually Transmitted Diseases, Viral
Candidiasis
Clotrimazole
Miconazole
Acquired Immunodeficiency Syndrome
Tioconazole
AIDS-Related Complex
Immunologic Deficiency Syndromes
Naphazoline

Virus Diseases
Oxymetazoline
Methadone
Mycoses
Guaifenesin
Phenylephrine
HIV Infections
Sexually Transmitted Diseases
Phenylpropanolamine
Retroviridae Infections

Additional relevant MeSH terms:

Anti-Infective Agents
Respiratory System Agents
RNA Virus Infections
Slow Virus Diseases
Immune System Diseases
Physiological Effects of Drugs
Central Nervous System Depressants
Narcotics
Infection
Pharmacologic Actions

Sensory System Agents
Antifungal Agents
Therapeutic Uses
Lentivirus Infections
Peripheral Nervous System Agents
Analgesics
Antitussive Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on January 15, 2009